Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.80 |
| ▸ | FAAH | O00519 | 8/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lactic Acid SCHEMBL3863099 | 1.00 | DNM1 (0.80) | DNM1FAAHNAAACASP2EPHX2 | |
| Lactic Acid SCHEMBL128277 | 1.00 | DNM1 (0.80) | DNM1FAAHNAAACASP2EPHX2 | |
| Lactic Acid SCHEMBL428727 | 1.00 | DNM1 (0.80) | DNM1FAAHNAAACASP2EPHX2 | |
| Lactic Acid SCHEMBL25266814 | 0.93 | DNM1 (0.79) | DNM1FAAHNAAACASP2EPHX2 | |
| Lactic Acid SCHEMBL432082 | 0.92 | DNM1 (0.68) | DNM1FAAHEPHX2KDM4EMEN1 | |
| Lactic Acid SCHEMBL28053597 | 0.92 | DNM1 (0.68) | DNM1FAAHEPHX2KDM4EMEN1 | |
| SCHEMBL8660980 | 0.89 | DNM1 (1.00) | DNM1FAAHNAAACASP2EPHX2 | |
| SCHEMBL5383341 | 0.89 | DNM1 (1.00) | DNM1FAAHNAAACASP2EPHX2 | |
| SCHEMBL9565176 | 0.89 | DNM1 (1.00) | DNM1FAAHNAAACASP2EPHX2 | |
| SCHEMBL19281112 | 0.89 | DNM1 (1.00) | DNM1FAAHNAAACASP2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117534966-A | Warm-mix type in-situ thermal regeneration asphalt mixture modifier and preparation method thereof | 山西交控科技转化有限公司 | 2024-02-09 | — | — | CN | claimed |
| US-20080113892-A1 | Antimicrobial wash formulations including amidoamine-based cationic surfactants | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2008-05-15 | — | — | US | claimed |
| CN-117551356-A | Environment-friendly direct-casting type waste rubber powder-based asphalt mixture modifier and preparation method thereof | 山西交控科技转化有限公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-117534966-A | Warm-mix type in-situ thermal regeneration asphalt mixture modifier and preparation method thereof | 山西交控科技转化有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11447640-B2 | Encapsulated materials with improved properties | SUN CHEMICAL CORPORATION (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3500601-B1 | ENCAPSULATED MATERIALS WITH IMPROVED PROPERTIES | SUN CHEMICAL CORP (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20210214561-A1 | ENCAPSULATED MATERIALS WITH IMPROVED PROPERTIES | SUN CHEMICAL CORPORATION (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3500601-A1 | ENCAPSULATED MATERIALS WITH IMPROVED PROPERTIES | Sun Chemical Corporation (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018035325-A1 | ENCAPSULATED MATERIALS WITH IMPROVED PROPERTIES | SUN CHEMICAL CORPORATION (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20100143274-A1 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | CIBA CORPORATION (US) | 2010-06-10 | — | — | US | disclosed |
| US-7517842-B2 | Antimicrobial wash formulations including amidoamine-based cationic surfactants | GOJO INDUSTRIES, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060104966-A1 | Transglutaminase linkage of agents to tissue | PERICOR SCIENCE, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-6958148-B1 | Linkage of agents to body tissue using microparticles and transglutaminase | PERICOR SCIENCE, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-6919076-B1 | Conjugates of agents and transglutaminase substrate linking molecules | PERICOR SCIENCE, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1303260-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | Pericor Science, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1203141-A1 | LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1202706-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002007707-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | PERICOR SCIENCE, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143274-A1 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | MAOA, MAOB, ACMSD | DNM1 2231/4885FAAH 243/4885NAAA 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.